Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C232H320Br12N32O116.Gd.H |
| Molecular Weight | 6530.27 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 68 / 68 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[Gd+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CN(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C(=O)C1=C(Br)C(C(=O)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C(Br)C(NC(=O)CNC(=O)C2=CC=C(NC(=O)C3=CC=C(NC(=O)CNC(=O)CCC[C@H](N4CCN(CCN(CCN(CC4)[C@@H](CCCC(=O)NCC(=O)NC5=CC=C(C=C5)C(=O)NC6=CC=C(C=C6)C(=O)NCC(=O)NC7=C(Br)C(C(=O)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C(Br)C(C(=O)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C7Br)C([O-])=O)[C@@H](CCCC(=O)NCC(=O)NC8=CC=C(C=C8)C(=O)NC9=CC=C(C=C9)C(=O)NCC(=O)NC%10=C(Br)C(C(=O)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C(Br)C(C(=O)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C%10Br)C([O-])=O)[C@@H](CCCC(=O)NCC(=O)NC%11=CC=C(C=C%11)C(=O)NC%12=CC=C(C=C%12)C(=O)NCC(=O)NC%13=C(Br)C(C(=O)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C(Br)C(C(=O)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C%13Br)C([O-])=O)C([O-])=O)C=C3)C=C2)=C1Br
InChI
InChIKey=SPEOBOARQOCRFA-GTPOWFTASA-K
InChI=1S/C232H324Br12N32O116.Gd/c233-165-157(221(377)269(61-113(293)181(337)197(353)129(309)77-277)62-114(294)182(338)198(354)130(310)78-278)169(237)177(170(238)158(165)222(378)270(63-115(295)183(339)199(355)131(311)79-279)64-116(296)184(340)200(356)132(312)80-280)261-153(333)57-249-213(369)93-13-37-105(38-14-93)257-217(373)97-21-29-101(30-22-97)253-149(329)53-245-145(325)9-1-5-109(229(385)386)265-45-47-266(110(230(387)388)6-2-10-146(326)246-54-150(330)254-102-31-23-98(24-32-102)218(374)258-106-39-15-94(16-40-106)214(370)250-58-154(334)262-178-171(239)159(223(379)271(65-117(297)185(341)201(357)133(313)81-281)66-118(298)186(342)202(358)134(314)82-282)166(234)160(172(178)240)224(380)272(67-119(299)187(343)203(359)135(315)83-283)68-120(300)188(344)204(360)136(316)84-284)49-51-268(112(232(391)392)8-4-12-148(328)248-56-152(332)256-104-35-27-100(28-36-104)220(376)260-108-43-19-96(20-44-108)216(372)252-60-156(336)264-180-175(243)163(227(383)275(73-125(305)193(349)209(365)141(321)89-289)74-126(306)194(350)210(366)142(322)90-290)168(236)164(176(180)244)228(384)276(75-127(307)195(351)211(367)143(323)91-291)76-128(308)196(352)212(368)144(324)92-292)52-50-267(48-46-265)111(231(389)390)7-3-11-147(327)247-55-151(331)255-103-33-25-99(26-34-103)219(375)259-107-41-17-95(18-42-107)215(371)251-59-155(335)263-179-173(241)161(225(381)273(69-121(301)189(345)205(361)137(317)85-285)70-122(302)190(346)206(362)138(318)86-286)167(235)162(174(179)242)226(382)274(71-123(303)191(347)207(363)139(319)87-287)72-124(304)192(348)208(364)140(320)88-288;/h13-44,109-144,181-212,277-324,337-368H,1-12,45-92H2,(H,245,325)(H,246,326)(H,247,327)(H,248,328)(H,249,369)(H,250,370)(H,251,371)(H,252,372)(H,253,329)(H,254,330)(H,255,331)(H,256,332)(H,257,373)(H,258,374)(H,259,375)(H,260,376)(H,261,333)(H,262,334)(H,263,335)(H,264,336)(H,385,386)(H,387,388)(H,389,390)(H,391,392);/q;+3/p-3/t109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191+,192+,193+,194+,195+,196+,197+,198+,199+,200+,201+,202+,203+,204+,205+,206+,207+,208+,209+,210+,211+,212+;/m0./s1
Gadomelitol (P792, Vistarem) is a monogadolinated contrast agent for magnetic resonance imaging (MRI) that originally was developed as a blood pool agent with rapid clearance and mainly free renal elimination. Gadomelitol could provide information on the interstitial fluid pressure (negatively associated with disease-free survival in locally advanced cervical carcinoma) of cervical carcinoma xenografts. Due to its slow extravasation and high tumor residence time, gadomelitol may potentially be useful to improve characterization between benign versus malignant tumors using dynamic MRI.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ML3LD67ALG
Created by
admin on Wed Apr 02 07:36:12 GMT 2025 , Edited by admin on Wed Apr 02 07:36:12 GMT 2025
|
PRIMARY | |||
|
300000034245
Created by
admin on Wed Apr 02 07:36:12 GMT 2025 , Edited by admin on Wed Apr 02 07:36:12 GMT 2025
|
PRIMARY | |||
|
126480316
Created by
admin on Wed Apr 02 07:36:12 GMT 2025 , Edited by admin on Wed Apr 02 07:36:12 GMT 2025
|
PRIMARY | |||
|
308814-41-7
Created by
admin on Wed Apr 02 07:36:12 GMT 2025 , Edited by admin on Wed Apr 02 07:36:12 GMT 2025
|
PRIMARY | |||
|
C174713
Created by
admin on Wed Apr 02 07:36:12 GMT 2025 , Edited by admin on Wed Apr 02 07:36:12 GMT 2025
|
PRIMARY | |||
|
8075
Created by
admin on Wed Apr 02 07:36:12 GMT 2025 , Edited by admin on Wed Apr 02 07:36:12 GMT 2025
|
PRIMARY |
ACTIVE MOIETY